Merck Asks FDA For ‘Emergency Use Authorization’ For COVID-19 Pill, Cuts ‘Risk Of Death Or Hospitalization By Approx. 50%’

Merck Asks FDA For ‘Emergency Use Authorization’ For COVID-19 Pill, Cuts ‘Risk Of Death Or Hospitalization By Approx. 50%’


Pharmaceutical company Merck announced Monday that they and Ridgeback Biotherapeutics were requesting emergency authorization from the U.S. Food and Drug Administration (FDA) for molnupiravir, its experimental antiviral COVID-19 pill.

“Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization,” Merck announced in a press release. “The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months.”

The request was based on “positive results from a planned interim analysis” which “evaluated molnupiravir in non-hospitalized adult patients with mild-to-moderate COVID-19 who were at risk for

Trending: Dr. Stella Immanuel: “The Whole Pandemic Was A TROJAN HORSE For Vaccines – Fauci Is Epitome Of Evil.”

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend